2.19.2 MILESTONES IN THE INTRODUCTION OF CONTINUOUS DOPAMINERGIC STIMULATION THERAPY FOR ADVANCED PARKINSON'S DISEASE

2012 ◽  
Vol 18 ◽  
pp. S90
Author(s):  
M. Mouradian
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Advanced Parkinson’S Disease ◽  
Continuous Dopaminergic Stimulation ◽  
Dopaminergic Stimulation

Beyond Motor Symptoms – Impact of Continuous Dopaminergic Stimulation on Non-motor and Social Aspects of Advanced Parkinson’s Disease

2012 ◽  
Vol 7 ((Suppl.1)) ◽  
pp. 17
Author(s):  
Barbara Pickut ◽  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Infusion Therapy ◽  
Motor Symptoms ◽  
Advanced Parkinson’S Disease ◽  
Continuous Dopaminergic Stimulation ◽  
Anxiety Depression ◽  
Non Motor Symptoms ◽  
Dopaminergic Stimulation

Two patient cases are presented here that illustrate the benefits of continuous dopaminergic stimulation on the non-motor symptoms of Parkinson’s disease. In both cases, levodopa/carbidopa intestinal gel infusion therapy led to improvements in anxiety, depression, concentration, urge incontinence, sexual function, sleep, vivid dreams and rapid eye movement sleep behaviour disorder, pain, sweating and feelings of self-assuredness. Such improvements have an impact on patients’ quality of life and can help their social functioning.

Continuous Dopaminergic Stimulation in Parkinson's Disease - What Have We Learned from Positron-emission Tomography?

2010 ◽  
Vol 5 (1) ◽  
pp. 22
Author(s):  
David J Brooks ◽  
Nicola Pavese ◽  
◽  
Keyword(s):  
Parkinson’S Disease ◽  
Positron Emission Tomography ◽  
Parkinson's Disease ◽  
Monoamine Oxidase Inhibitor ◽  
Oxidase Inhibitor ◽  
Emission Tomography ◽  
Continuous Dopaminergic Stimulation ◽  
Positron Emission ◽  
Significant Step ◽  
Dopaminergic Stimulation

The hypothesis that pulsatile stimulation of striatal dopamine receptors in Parkinson's disease (PD) induces molecular and physiological changes in basal ganglia neurons and may contribute to the development of motor complications has led to the design of therapeutic strategies that provide more continuous dopaminergic stimulation. Newer agents and drug-delivery systems, such as slow-release preparations, catechol- O-methyltransferase and monoamine oxidase inhibitor agents, apomorphine and Duodopa™infusions, represent a significant step towards less pulsatile dopaminergic administration. However, their efficacy in providing steady brain levels of dopaminergic stimulation in the short and longer term has not yet been proved in patients. This article briefly reviews and discusses the findings of published positron-emission tomography (PET) studies that support or oppose the value of continuous dopaminergic stimulation in PD. The potential future value of PET for proof of mechanism in this area is also debated.

Continuous Transdermal Dopaminergic Stimulation in Advanced Parkinson's Disease

2001 ◽  
Vol 24 (3) ◽  
pp. 163-169 ◽  
Author(s):  
Leo Verhagen Metman ◽  
Marge Gillespie ◽  
Carrie Farmer ◽  
Francesco Bibbiani ◽  
Spiridon Konitsiotis ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Advanced Parkinson’S Disease ◽  
Dopaminergic Stimulation
Sign in / Sign up

Export Citation Format

Share Document